URGNUroGen Pharma Ltd.Signing up patients
A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer
Upper Urinary Tract Urothelial Carcinoma · Urothelial Carcinoma
5Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +5.1
2 insiders sold shares within a month
Since Sep 8, 2026 · was worth 10, fading over time
Worry score5
Score over time
- Stage
- Phase 3
- Patients
- 70 (planned)
- Started
- Aug 6, 2025
- Main results expected
- Mar 2027
- Fully finished
- Mar 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Complete response rate (CRR)
Measured over: 3 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 10, now 5.1, since 2026-09-08, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06774131 · record last updated 2026-09-03 · checked 2026-11-09 15:47 UTC